10x Genomics Demonstrates Breadth, Scale and Leadership at 2023 AGBT General Meeting
Ultima Genomics Announces Collaboration With 10x Genomics to Enable Seamless Integration of Chromium Single Cell Applications on Ultima Sequencers
NEWARK, Calif., Feb. 6, 2023 /PRNewswire/ -- Ultima Genomics, Inc. and 10x Genomics today announced a collaboration to integrate use of the 10x Genomics Chromium Single Cell Gene Expression solution
Rockefeller Capital Management L.P. Increases Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)
Rockefeller Capital Management L.P. increased its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Rating) by 95.2% during the third quarter, according to its most recent filing with the S
UBS Group Begins Coverage on 10x Genomics (NASDAQ:TXG)
UBS Group started coverage on shares of 10x Genomics (NASDAQ:TXG – Get Rating) in a research report released on Thursday, The Fly reports. The brokerage issued a neutral rating and a $50.00 price tar
10x Genomics (NASDAQ:TXG) Now Covered by Analysts at UBS Group
UBS Group assumed coverage on shares of 10x Genomics (NASDAQ:TXG – Get Rating) in a research report report published on Thursday, The Fly reports. The brokerage issued a neutral rating and a $50.00 p
10x Genomics Initiated at Neutral by UBS
10x Genomics Price Target Announced at $50.00/Share by UBS
The Past Three Years for 10x Genomics (NASDAQ:TXG) Investors Has Not Been Profitable
It is a pleasure to report that the 10x Genomics, Inc. (NASDAQ:TXG) is up 49% in the last quarter. But that doesn't change the fact that the returns over the last three years have been less than pl
UBS Initiates Coverage On 10x Genomics With Neutral Rating, Announces Price Target of $50
UBS analyst John Sourbeer initiates coverage on 10x Genomics (NASDAQ:TXG) with a Neutral rating and announces Price Target of $50.
10x Genomics Initiated With a Neutral at UBS
Loading...
No Stock Yet